Microscopic Polyangiitis Market report provides key enumeration on the Market status of the Microscopic Polyangiitis manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. The research was conducted using an objective combination of primary and secondary information including inputs from key participants in the Microscopic Polyangiitis industry. It delivers important information to identify and analyse the market need, market Growth and competition. Microscopic Polyangiitis Industry report anlayzes Market for Microscopic Polyangiitis Market Research Report information: by Drug (Rituximab, Azathioprine, Cyclophosphamide, Prednisone, Pipeline drugs (Abatacept and IFX 1), and Others), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast Till 2026.
Microscopic polyangiitis (MPA) occurs due to inflammation of blood vessels resulting in damage to other organs, mostly kidney, lungs, nerves, skin, and joints. MPA is an immune system mediated disorder, however the exact reason leading to immune system dysfunction is unknown. Since MPA affects multiple organs, various symptoms such as illness, fatigue, fever, loss of weight and appetite, coughing blood in case of lungs, and loss of sensation in case of nerves can be seen. Diagnosis involves blood test for antineutrophil cytoplasmic antibodies (ANCA), urine test for detection of red blood cells (RBCs), and imaging techniques such as computed tomography (CT), magnetic resonance (MR) scan, and X-rays. If results of these tests are positive for presence of MPA, biopsy (tissue sample testing) is performed for confirmation of presence of MPA.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2529
Microscopic Polyangiitis Market Drivers
In the recent past, various regulatory bodies such as European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), Medicines and Healthcare products Regulatory Agency (MHRA), and others have granted treatment related approvals. Such treatment approvals are expected to propel the global microscopic polyangiitis market growth over the forecast period. For instance, in October 2018, Genentech, Inc., a San Francisco-based biotechnology company, received approval from the U.S. Food and Drug Administration (FDA) to update the Rituxan label to include the follow-up treatment information of adult patients suffering from granulomatosis with polyangiitis and microscopic polyangiitis, who had shown improvement in medical condition with the glucocorticoid and cyclophosphamide induction treatment.
Launch of new treatment methods by key players is expected to drive the global microscopic polyangiitis market growth over the forecast period. For instance, in July 2018, InflaRx N.V., a German clinical stage bio-pharmaceutical company, received an approval from the U.S. Food and Drug Administration (FDA) for conducting phase-2 clinical trials to assess the safety and effectiveness of IFX-1 for treatment of anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis, presence of which indicates that the patient is suffering from microscopic polyangiitis. IFX-1 is an inhibitor of the complement system (a component of immune system) and neutralizes C5a component without affecting the normal immune functions. These factors are expected to drive the global microscopic polyangiitis market growth over the forecast period.
Microscopic Polyangiitis Market Restraints
The corticosteroids have side effects, which include skin thinning and intense pain. The monoclonal antibody production involves costly and time consuming research. Azathioprine involves side effects such as diarrhea, joint pain, loss of coordination, seizure, and vision changes. These factors are expected to restrain the global microscopic polyangiitis market growth over the forecast period.
Microscopic Polyangiitis Market Regional Analysis
Europe microscopic polyangiitis market is expected to witness significant growth over the forecast period, owing to proposed product launches. For instance, Bristol-Myers Squibb Company is conducting phase lll clinical trials for Abatacept (Orencia), which is expected to be completed by September 2022. Orencia is a recombinant protein, which inhibits the T lymphocyte activation pathway, thereby suppressing the immune system.
In March 2018, Amerigen Pharmaceuticals Limited, a China-based generic pharmaceutical company, was granted approval for its Abbreviated New Drug Application (‘ANDA’), by the U.S. FDA, for its cyclophosphamide capsules 25mg and 50mg. Cyclophosphamide is an immunosuppressive agent used for the treatment of microscopic polyangiitis in combination with corticosteroids. This is expected to propel the Asia Pacific microscopic polyangiitis market growth over the forecast period in turn supporting global microscopic polyangiitis market growth.
Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/microscopic-polyangiitis-market-2529
Microscopic Polyangiitis Market Key Players
Some of the key players operating in the global microscopic polyangiitis market include:
- Genentech, Inc.
- Celltrion, Inc.
- InflaRx N.V.
- ChemoCentryx Inc.
- Bristol-Myers Squibb Company
- Teijin Pharma Ltd
- Amerigen Pharmaceuticals Limited
- Sandoz International GmbH (Novartis Division)
- TTY Biopharm Company Ltd.
Microscopic Polyangiitis Market Taxonomy
- Pipeline drugs
- IFX 1
By Route of Administration
By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- North America
- Latin America
- Asia Pacific
- Middle East
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Name: Mr. Raj Shah
Phone: US +12067016702 / UK +4402081334027